Cagrilintide Dosage and Price Guide: Trial Ranges, 10 mg Vial Math, and Buyer Checks

Short Answer: Use Trial Doses as Evidence Benchmarks, Then Compare Verified Value

Cagrilintide, also called Cagri or NNC0174-0833, is a stable, lipidated long-acting amylin analogue developed for once-weekly study dosing. The standalone Phase 2 trial tested 0.3, 0.6, 1.2, 2.4, and 4.5 mg once weekly. Those are evidence benchmarks, not a personalized protocol.

For buyers comparing 10 mg research vials, one fact anchors all the math: 10 mg equals 10,000 mcg. Adding more or less water changes concentration, draw volume, and syringe units. It does not change the total peptide mass.

The best buying order is straightforward:

1. Confirm exact cagrilintide identity and match the COA to the current lot.
2. Calculate concentration for the intended final volume.
3. Compare delivered cost per verified milligram at /prices/cagrilintide.
4. Review vendor testing at /vendors.
5. Apply the current code from /deals only after the evidence matches.

Start with the compound guide at /peptides/cagrilintide. The cheapest sticker price matters only when identity, vial size, lot evidence, and delivered cost are comparable.

What Cagrilintide Is and Why Amylin Differs From GLP-1

Natural amylin is released alongside insulin and helps promote satiety. Cagrilintide was engineered as a stable, long-acting analogue for obesity research. It is not semaglutide. Cagrilintide acts through amylin and calcitonin-family receptor biology, while semaglutide targets GLP-1 receptors.

The complementary pathways explain why the CagriSema clinical program pairs cagrilintide 2.4 mg with semaglutide 2.4 mg. Keep standalone and combination evidence separate. The full CagriSema result cannot be credited to cagrilintide alone.

Human Trial Data: Standalone Cagrilintide

Phase 2 trial NCT03856047 randomized 706 adults without diabetes across 57 sites in 10 countries. Participants received cagrilintide 0.3, 0.6, 1.2, 2.4, or 4.5 mg once weekly for 26 weeks, including dose escalation lasting up to 6 weeks, followed by 6 weeks of follow-up.

Across the 0.3 to 4.5 mg groups, mean weight reduction ranged from 6.0% to 10.8%, or 6.4 to 11.5 kg. Placebo produced 3.0%, or 3.3 kg. At 4.5 mg, cagrilintide reached 10.8%, or 11.5 kg, compared with 9.0%, or 9.6 kg, for daily liraglutide 3.0 mg. The difference was 1.8 percentage points with p=0.03.

Tolerability changed with dose. Gastrointestinal adverse events occurred in 41% to 63% of cagrilintide groups versus 32% with placebo. Nausea occurred in 20% to 47% versus 18%. Permanent treatment discontinuation affected 73 participants, or 10% overall. Adverse events accounted for 30 discontinuations, or 4% overall.

Those numbers make the standalone trial useful for understanding both the dose-response signal and the tradeoffs observed in humans. They do not establish that every research vial has the same identity, content, purity, or handling quality as the clinical material.

Combination Evidence: Phase 1b and REDEFINE 1

Phase 1b trial NCT03600480 randomized 96 people and exposed 95. It tested cagrilintide 0.16, 0.30, 0.60, 1.2, 2.4, or 4.5 mg once weekly with semaglutide 2.4 mg. Doses were co-escalated every 4 weeks over 16 weeks, held at target for 4 weeks, then followed for 5 weeks.

Cagrilintide's measured half-life was 159 to 195 hours, with median time to maximum concentration of 24 to 72 hours. At week 20, the cagrilintide 1.2 and 2.4 mg combination groups changed by -15.7% and -17.1%, versus -9.8% for pooled placebo plus semaglutide. The 4.5 mg combination changed by -15.4%, versus -8.0% for matched placebo plus semaglutide.

REDEFINE 1, NCT05567796, followed 3,417 adults without diabetes for 68 weeks. Allocation was 2,108 to CagriSema, 302 to semaglutide 2.4 mg, 302 to cagrilintide 2.4 mg, and 705 to placebo.

The treatment-policy estimate showed mean weight change of -20.4% for CagriSema versus -3.0% for placebo, a -17.3 percentage-point difference with a 95% confidence interval of -18.1 to -16.6 and p<0.001. Gastrointestinal adverse events occurred in 79.6% versus 39.9% and were mainly transient and mild to moderate.

You may also see a 22.7% headline. That is the adherence-focused estimate. The PubMed abstract's treatment-policy estimate is 20.4%. Both need their estimand labeled, and neither should be presented as a standalone cagrilintide result.

10 mg Cagrilintide Reconstitution Math

A U-100 syringe has 100 units per mL, so one unit equals 0.01 mL. These calculations translate studied amounts into concentration and syringe units. They are vial arithmetic, not a personalized recommendation.

With a 1 mL final volume, the concentration is 10 mg/mL and each U-100 unit contains 100 mcg:

• 0.3 mg = 3 units
• 0.6 mg = 6 units
• 1.2 mg = 12 units
• 2.4 mg = 24 units
• 4.5 mg = 45 units

With a 2 mL final volume, the concentration is 5 mg/mL and each unit contains 50 mcg:

• 0.3 mg = 6 units
• 0.6 mg = 12 units
• 1.2 mg = 24 units
• 2.4 mg = 48 units
• 4.5 mg = 90 units

With 2.5 mL, the concentration is 4 mg/mL and each unit contains 40 mcg, so 2.4 mg equals 60 units. With 3 mL, the concentration is about 3.333 mg/mL and each unit contains about 33.33 mcg, so 2.4 mg equals 72 units.

Use /tools/reconstitution-calculator to run custom vial, water, and target-amount math. The handling context is covered in /blog/peptide-reconstitution-bac-water-buyer-guide. If you want pre-computed tables across injectable compounds, The Peptide Handbook covers them at /handbook?src=blog.

Ten divided by 2.4 equals 4.167 theoretical amounts. Four complete 2.4 mg amounts use 9.6 mg and leave 0.4 mg before handling loss. Water volume never changes that count.

Current Cagrilintide Prices

PeptidePub's September 3, 2026 catalog snapshot tracks 12 cagrilintide listings across 5 mg and 10 mg vials.

The 10 mg list prices are:

• Double R: $69.99
• AMP: $88
• Valor: $99.99
• Level Up: $100
• Valkyrie: $101.50
• Glacier: $101.99
• Mile High: $119.99
• Ascension: $120
• World Wide: $308

The 5 mg list prices are AMP at $49, Glacier at $56.99, and World Wide at $197.

Do not compare those totals without normalizing vial size. Start at /prices/cagrilintide, then use /tools/cost-per-dose after matching exact identity, vial size, lot evidence, and delivered price.

After current codes, the strongest normalized examples are Double R 10 mg at $59.49, or $5.95 per mg and $14.28 per theoretical 2.4 mg; Ascension 10 mg at $60, or $6.00 per mg and $14.40 per 2.4 mg; and AMP 10 mg at $79.20, or $7.92 per mg and $19.01 per 2.4 mg.

Across all tracked sizes, after-code cost spans about $5.95 to $37.43 per mg and $14.28 to $89.83 per theoretical 2.4 mg. Those figures exclude shipping, tax, payment fees, and handling loss, so final checkout cost can change the ranking.

Full After-Code Value Comparison

Here is the complete normalized snapshot, listed as after-code total, price per mg, and theoretical material cost per 2.4 mg:

• Double R 10 mg: $59.49, $5.95/mg, $14.28
• Ascension 10 mg: $60, $6.00/mg, $14.40
• AMP 10 mg: $79.20, $7.92/mg, $19.01
• AMP 5 mg: $44.10, $8.82/mg, $21.17
• Valor 10 mg: $89.99, $9.00/mg, $21.60
• Level Up 10 mg: $90, $9.00/mg, $21.60
• Valkyrie 10 mg: $91.35, $9.13/mg, $21.92
• Glacier 10 mg: $91.79, $9.18/mg, $22.03
• Glacier 5 mg: $51.29, $10.26/mg, $24.62
• Mile High 10 mg: $107.99, $10.80/mg, $25.92
• World Wide 10 mg: $292.60, $29.26/mg, $70.22
• World Wide 5 mg: $187.15, $37.43/mg, $89.83

The current PEPTIDEPUB code gives 50% off at Ascension, 15% at Double R, 10% at AMP, Glacier, Level Up, Mile High, Valkyrie, and Valor, and 5% at World Wide.

Check /deals immediately before checkout because codes and inventory can change. Then compare the full delivered cost rather than treating a discount percentage as the result. A larger code can produce a better price, but only a matching lot COA and measured content tell you whether the milligrams are verified.

COA and Vendor Testing Checks Before Buying

A useful cagrilintide COA should name the exact peptide, match the batch or lot on the vial, identify the testing laboratory, and show the report date. Look for LC-MS identity, HPLC or UPLC purity, and quantitative net content. For an injectable format, stronger evidence also includes sterility, endotoxin, heavy-metal, and contaminant testing.

Purity alone is not enough. A report can show that the tested material was highly pure without proving that a vial contains the advertised number of milligrams. Quantitative content closes that gap.

PeptidePub's current vendor-level testing-depth checkpoints are:

• Double R and World Wide: 7/7
• Ascension, Glacier, and Mile High: 6/7
• Valor: 5/7
• AMP and Valkyrie: 3/7
• Level Up: 2/7

These scores summarize published vendor testing fields. They do not prove that every current cagrilintide lot has all seven items, so verify the exact lot before paying.

Use /methodology for how PeptidePub evaluates vendors and /blog/how-to-read-peptide-coa-before-you-buy for the document workflow. Once identity, lot proof, and delivered value all pass, /go/bodybuilding-health is the verified affiliate route for the tracked research-vendor offer.

That sequence matters. First verify what is in the vial. Then compare price per verified milligram. Finally, apply the live deal and check the delivered total.

FAQ

What cagrilintide doses were studied?

The standalone Phase 2 trial tested 0.3, 0.6, 1.2, 2.4, and 4.5 mg once weekly. Phase 1b combination research also included 0.16 mg. These are trial benchmarks, not a universal schedule.

How many units is 2.4 mg from a 10 mg vial?

It depends on final volume. The arithmetic is 24 U-100 units at 1 mL, 48 units at 2 mL, 60 units at 2.5 mL, or 72 units at 3 mL.

How many 2.4 mg amounts are in a 10 mg vial?

There are four complete theoretical amounts. They use 9.6 mg and leave 0.4 mg before handling loss. The mathematical quotient is 4.167.

Is cagrilintide the same as semaglutide?

No. Cagrilintide is a long-acting amylin analogue. Semaglutide is a GLP-1 receptor agonist. The CagriSema clinical program combines cagrilintide 2.4 mg with semaglutide 2.4 mg, so combination outcomes should stay labeled as combination evidence.

What should a cagrilintide COA show?

Look for exact identity, a lot matching the vial, a named laboratory, test date, LC-MS identity, HPLC or UPLC purity, and measured net content. Broader injectable-product evidence can include sterility, endotoxin, heavy metals, and contaminant screening. A purity percentage by itself does not establish how many milligrams are in the vial.

Bottom Line

Cagrilintide has meaningful standalone human data across 0.3 to 4.5 mg once-weekly trial groups, plus a distinct amylin mechanism that complements GLP-1 biology. The combination data are also substantial, but the CagriSema outcomes must remain labeled as combination evidence.

Buyer interest is not hypothetical. Cagrilintide holds demand rank 6 in PeptidePub's current catalog, and a September 3, 2026 search returned multiple dedicated dosage calculators and guides alongside the primary Phase 2 result. That makes accurate math and current vendor comparisons especially valuable.

For a 10 mg research vial, use this checklist:

1. Verify exact cagrilintide identity and current lot evidence.
2. Calculate concentration at /tools/reconstitution-calculator.
3. Compare live price per mg at /prices/cagrilintide.
4. Inspect published vendor evidence at /vendors.
5. Apply the latest code from /deals after the proof matches.

The strongest after-code value checkpoints in the September 3 snapshot are Double R at about $5.95 per mg and Ascension at $6.00 per mg. Delivered cost, current stock, and exact lot evidence decide the final ranking.

For adjacent reading, see /blog/retatrutide-dosing-trials-1-4-8-12-mg for another trial-dose breakdown and /blog/peptide-reconstitution-bac-water-buyer-guide for handling context. The practical rule is simple: verify the vial first, normalize the price second, and never buy cagrilintide without checking PeptidePub's current comparison.